These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 36388140)

  • 21. The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences.
    Millard SJ; Weston-Green K; Newell KA
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109908. PubMed ID: 32145362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.
    Jha MK; Trivedi MH
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29329256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the relationship between proinflammatory cytokines and major depressive disorder.
    Young JJ; Bruno D; Pomara N
    J Affect Disord; 2014 Dec; 169():15-20. PubMed ID: 25128861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology.
    Belleau EL; Treadway MT; Pizzagalli DA
    Biol Psychiatry; 2019 Mar; 85(6):443-453. PubMed ID: 30470559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression.
    Won E; Na KS; Kim YK
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The fibrinolytic system: A new target for treatment of depression with psychedelics.
    Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
    Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis.
    Liu JJ; Wei YB; Strawbridge R; Bao Y; Chang S; Shi L; Que J; Gadad BS; Trivedi MH; Kelsoe JR; Lu L
    Mol Psychiatry; 2020 Feb; 25(2):339-350. PubMed ID: 31427752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the Role of Oxidative Stress, Neuroinflammation and Abnormal Myelination in Excessive Aggression Associated with Depression: Recent Input from Mechanistic Studies.
    Gorlova A; Svirin E; Pavlov D; Cespuglio R; Proshin A; Schroeter CA; Lesch KP; Strekalova T
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroplasticity and memory formation in major depressive disorder: an imaging genetics perspective on serotonin and BDNF.
    Kuhn M; Popovic A; Pezawas L
    Restor Neurol Neurosci; 2014; 32(1):25-49. PubMed ID: 23603442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review.
    Demchenko I; Tassone VK; Kennedy SH; Dunlop K; Bhat V
    Front Psychiatry; 2022; 13():864902. PubMed ID: 35722550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation, serotonin and major depression.
    Catena-Dell'Osso M; Rotella F; Dell'Osso A; Fagiolini A; Marazziti D
    Curr Drug Targets; 2013 May; 14(5):571-7. PubMed ID: 23531160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.
    Edem EE; Anyanwu CC; Nebo KE; Akinluyi ET; Fafure AA; Ishola AO; Enye LA
    Psychopharmacology (Berl); 2022 Jan; 239(1):185-200. PubMed ID: 34792632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases.
    Dawood S; Bano S; Badawy AA
    Biosci Rep; 2022 May; 42(5):. PubMed ID: 35506370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.
    Duncan WC; Ballard ED; Zarate CA
    Handb Exp Pharmacol; 2019; 253():337-358. PubMed ID: 28939975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder.
    Jeon SW; Kim YK
    J Inflamm Res; 2018; 11():179-192. PubMed ID: 29773951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.
    Pitsillou E; Bresnehan SM; Kagarakis EA; Wijoyo SJ; Liang J; Hung A; Karagiannis TC
    Mol Biol Rep; 2020 Jan; 47(1):753-770. PubMed ID: 31612411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin E for the management of major depressive disorder: possible role of the anti-inflammatory and antioxidant systems.
    Manosso LM; Camargo A; Dafre AL; Rodrigues ALS
    Nutr Neurosci; 2022 Jun; 25(6):1310-1324. PubMed ID: 33314993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
    Dos Santos RG; Hallak JE; Baker G; Dursun S
    J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cortisol and Major Depressive Disorder-Translating Findings From Humans to Animal Models and Back.
    Nandam LS; Brazel M; Zhou M; Jhaveri DJ
    Front Psychiatry; 2019; 10():974. PubMed ID: 32038323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD).
    Mosiołek A; Pięta A; Jakima S; Zborowska N; Mosiołek J; Szulc A
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33920992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.